Five Prime Therapeutics (FPRX) Misses Q4 EPS by 16c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.73), $0.16 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Vireo Growth completes acquisition of C21 Investments
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance